A blueprint for a healthier tomorrow
We design and develop precision therapies, with the goal of transforming patient care. These include multiple programs for genomically defined cancers, rare diseases and cancer immunotherapy.
Our pipelinePowerful precision
Our uniquely targeted, scalable approach empowers the rapid design and development of new precision therapies and increases the likelihood of clinical success.
Our platformA promise to change the paradigm
We strive to improve human health with transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease.
Our companyDiversity sparks imagination
Our diverse team is passionate about science and thrives on working together to achieve the impossible. We use every opportunity to think differently, make bold decisions and pioneer novel solutions.
Our opportunitiesOur 2020 Blueprint
2
marketed products
4
pending
marketing
applications
marketing
applications
6
clinical-stage
therapeutic
candidates
therapeutic
candidates
8
research
programs
programs
Our “2020 Blueprint” strategy establishes a planned path to transform Blueprint Medicines, by the end of 2020, into a global commercial enterprise focused on delivering a portfolio of precision therapies to patients with cancer and rare diseases. See our press release.
Recent News
Dec 02, 2018
Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
Events and presentations
Dec 02, 2018
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) (oral presentation)
Nov 15, 2018
Blueprint Medicines CTOS Conference Call
Our commitment to patients
At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.
Read onOur investigational precision therapies
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).
Meet the Blue Crew
Meet the Blue Crew
Corinne, Senior Clinical Program Manager
I lead clinical operations for BLU-667, an investigational therapy for people with RET-altered cancers. My job is to plan and lead clinical trials to support our goal of delivering this potentially transformative new medicine to patients quickly and responsibly.
Read onWe aspire to pioneer new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit The Lens.
Read on
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Jeff Albers,
Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Jeff Albers, Chief Executive Officer
Dare to be different
A strong team embraces different perspectives, opinions and ideas. We believe each level of our company should reflect our team’s diversity—and its excellence.
Read on